Genelux Corporation Common Stock

GNLXNASDAQ • USD
ThemeHealthcare - Oncology›Immunotherapy & Immuno-Oncology
2.60 USD
↘ 0.01 (0.19%)🟢LIVE (AS OF 11:17 AM EDT)
🟢Market: OPEN

GNLX is currently priced at $2.60. GNLX shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Furthermore, GNLX is currently richly valued, trading at a premium to sector peers across key valuation metrics.

Technical & fundamental data as of Oct 5, 2026.

Open?$2.58
High?$2.63
Low?$2.48
Prev. Close?$2.60
Volume?25.6K
Avg. Volume?279.7K
VWAP?$2.57
Rel. Volume?0.09x
Bid / Ask
Bid?$2.56 × 100
Ask?$2.60 × 100
Spread?$0.04
Midpoint?$2.58
Valuation & Ratios
Market Cap?117.6M
Shares Out?45.2M
Float?38.3M
Float %?85.3%
P/E Ratio?N/A
P/B Ratio?7.30
EPS?-$0.79
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Themes
Healthcare - Oncology›Immunotherapy & Immuno-OncologyHealthcare - Genomics & Precision Medicine›Gene Therapy & Gene Editing
Employees
26
Market Cap
117.6M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.genelux.com
Listed
2023-01-26
Address
2625 TOWNSGATE ROAD, SUITE 230
WESTLAKE VILLAGE, CA 91361
Phone: 805-267-9889
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
23
Piotroski F-Score?0/9Weak
Altman Z-Score?-13.21Distress
Confidence?64%Moderate
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?10.71%High
Short Interest?4.1M
Days to Cover?14.4
Free Float38.3M
Avg Daily Volume284.3K
Settlement Date2026-09-15
Financial Health
Current Ratio?2.39Strong
Quick Ratio?2.39Strong
Cash Ratio?1.15Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
58/100
P/E?
N/A▾
P/B?
Peers
100
S&P
26
7.30FAIR▾
P/S?
Peers
100
S&P
3
14,704.73HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.0CHEAP▾
EV/Sales?
Peers
100
S&P
3
13,556.73HIGH▾
Returns & Efficiency
ROE?
S&P
3
-220.9%WEAK▾
ROA?
S&P
3
-135.8%WEAK▾
Cash Flow & Enterprise
FCF?$-28683000
Enterprise Value?$108.5M
Fundamentals ratios updated end of day
MarketsMoversWatchlist